Abstract:OBJECTIVES: Cell-free DNA based non-invasive prenatal testing (NIPT) has been shown with closeto-diagnosis sensitivity and specificity in detecting fetal T21, T18, and T13. Future development of this technology focuses on detection of other chromosomal aneuploidies, and more importantly chromosome copy number variants (CNVs) and single-gene mutations. Validation studies were carried out to demonstrate the feasibility of detecting CNVs and single-gene disease by exploiting the cell-free DNA testing strategy and existing NIPT platforms. METHOD: For testing CNVs, 35 plasma samples with known fetal CNVs (>10 Mb in size) were recruited, together with 1077 plasma samples with normal fetal karyotypes as the control. The samples were blindly tested using the routine NIPT testing pipelines adopted at the clinical laboratories of BGI, and analyzed with the proprietary FCAPS protocol. Results were compared to the karyotyping results to calculate the sensitivity and specificity of the NIPT test. For testing single-gene disease, we developed a unique haplotype-assisted approach which was validated in a Maple Syrup Urine Disease (MSUD) case. In a trio family (father, mother in early pregnancy, and proband), targeted sequencing (180X) of the known genes causing MSUD was used to identify the disease causative mutations in the proband child and parents. At 13 gestational weeks, maternal plasma DNA and genomic DNA of the trio family were tested with a customized array at the sequencing depth of 40X and 20X respectively to retrieve the SNPs information for the purpose of parental haplotypes deduction. Linkage analysis and Hidden Markov Model were then used to construct the fetal genotype and haplotype flanking the MSUD mutation region. RESULTS: For CNV detection, with on average 4–5 M reads per sample and the existing NIPT platforms, we were able to use the FCAPS analytic protocol to identify 32 positive samples in total of 35, and generated 6 false positive cases, leading to overall sensitivity and specificity of 91.4% and 99.4% respectively. False positive rate and false negative rate of the test were 0.56% and 0.28% respectively. We also showed that with an increased sequencing depth, the detection power of the test can be further improved. In the MUSD case, deep targeted sequencing in the trio family identified that the proband child carries a missense mutation and a large deletion on BCKDHA gene, which were inherited from the mother and father respectively. With the SNP markers of the proband and parents, parental haplotype of chromosome 19 in 6148 loci were recovered. After fetal haplotype construction, the same alleles as that of the proband in the causative gene BCKDHA were inherited to the fetus, indicating that the fetus is a MSUD patient. This result was later confirmed by invasive diagnosis, and led to a well-informed decision after post-test counselling. CONCLUSIONS: We demonstrate the successful application of NIPT in detection of CNVs larger than 10 Mb without changing much to the current pipelines of aneuploidy detection. It has the potential to be integrated into the current NIPT test and offer extra benefits to the clinical service. The haplotype-assisted approach we developed requires minimum genetic information to accurately predict fetal condition. It has the clinical potential for noninvasive prenatal diagnosis of single gene disease for family with a proband child and seeks a second healthy child.

Clinical exome sequencing as the first-tier test for diagnosing developmental disorders covering both CNV and SNV: a Chinese cohort

High positive predictive value of CNVs detected by clinical exome sequencing in suspected genetic diseases

Noninvasive detection of chromosomal CNV and single gene disease by massively parallel sequencing of cfDNA

Genetic Analysis of Children with Unexplained Developmental Delay And/or Intellectual Disability by Whole-Exome Sequencing.

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Diagnostic Yield and Novel Candidate Genes for Neurodevelopmental Disorders by Exome Sequencing in an Unselected Cohort with Microcephaly

Chromosomal Microarray Analysis in Developmental Delay and Intellectual Disability with Comorbid Conditions

Genetic and phenotypic analysis of 225 Chinese children with developmental delay and/or intellectual disability using whole-exome sequencing

Clinical Application of Chromosome Microarray Analysis in Han Chinese Children with Neurodevelopmental Disorders

Chromosomal Aberrations in Pediatric Patients with Moderate/Severe Developmental Delay/Intellectual Disability with Abundant Phenotypic Heterogeneities: A Single-center Study

Whole-exome sequencing as the first-tier test for patients in neonatal intensive care unit: a Chinese single-center study

The combination of whole-exome sequencing and copy number variation sequencing enables the diagnosis of rare neurological disorders.

Rare Copy Number Variations and Predictors in Children With Intellectual Disability and Epilepsy.

Molecular characterization for neurodevelopmental disorders by chromosomal microarray analysis

Exome sequencing in 90 children with developmental delay: a single-center experience

CNVbase: Batch Identification of Novel and Rare Copy Number Variations Based on Multi-Ethnic Population Data.

Use of medical exome sequencing for identification of underlying genetic defects in NICU: Experience in a cohort of 2303 neonates in China

[Diagnostic value of whole exome sequencing for patients with intellectual disability or global developmental delay]

Detection of Disease-Causing SNVs/Indels and CNVs in Single Test Based on Whole Exome Sequencing: A Retrospective Case Study in Epileptic Encephalopathies

Copy number variation sequencing for comprehensive diagnosis of chromosome disease syndromes.

Genetic Diagnostic Evaluation of Trio-Based Whole Exome Sequencing among Children with Diagnosed or Suspected Autism Spectrum Disorder